ERBB2 and breast carcinoma: Our method for the establishment of trastuzumab-resistant HER2/neu-overexpressing breast cancer cells is similar to that of Nahta et al (2004) and could provide a model for the investigation of the molecular mechanisms of trastuzumab resistance.